Gilead Sciences (NASDAQ:GILD) Stock Rating Upgraded by DZ Bank

Gilead Sciences (NASDAQ:GILD) was upgraded by stock analysts at DZ Bank from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Thursday,Briefing.com Automated Import reports. The brokerage presently has a $108.00 target price on the biopharmaceutical company’s stock. DZ Bank’s price objective suggests a potential upside of 4.54% from the stock’s previous close.

GILD has been the subject of several other research reports. Wolfe Research initiated coverage on Gilead Sciences in a research report on Friday, November 15th. They issued an “outperform” rating and a $110.00 price target for the company. JPMorgan Chase & Co. lifted their price objective on shares of Gilead Sciences from $105.00 to $115.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 29th. Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a report on Wednesday. Wells Fargo & Company upped their target price on Gilead Sciences from $105.00 to $120.00 and gave the company an “overweight” rating in a research note on Wednesday. Finally, Truist Financial lifted their price target on shares of Gilead Sciences from $83.00 to $97.00 and gave the company a “hold” rating in a research note on Friday, November 8th. Eleven investment analysts have rated the stock with a hold rating, fourteen have issued a buy rating and four have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $101.33.

Gilead Sciences Stock Performance

NASDAQ GILD opened at $103.31 on Thursday. The business has a 50-day moving average price of $93.14 and a 200-day moving average price of $87.12. The firm has a market cap of $128.75 billion, a price-to-earnings ratio of 1,147.89, a price-to-earnings-growth ratio of 1.25 and a beta of 0.18. Gilead Sciences has a twelve month low of $62.07 and a twelve month high of $104.71. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, beating analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. As a group, equities research analysts predict that Gilead Sciences will post 4.35 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total value of $228,375.00. Following the sale, the chief financial officer now directly owns 129,873 shares in the company, valued at approximately $11,863,898.55. The trade was a 1.89 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Merdad Parsey sold 164,211 shares of Gilead Sciences stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $91.92, for a total transaction of $15,094,275.12. Following the sale, the insider now owns 80,801 shares of the company’s stock, valued at approximately $7,427,227.92. This represents a 67.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 572,824 shares of company stock valued at $53,611,715 over the last ninety days. Company insiders own 0.16% of the company’s stock.

Hedge Funds Weigh In On Gilead Sciences

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Resona Asset Management Co. Ltd. purchased a new stake in shares of Gilead Sciences in the 4th quarter valued at approximately $39,908,000. First Western Trust Bank lifted its stake in Gilead Sciences by 1.8% in the fourth quarter. First Western Trust Bank now owns 56,093 shares of the biopharmaceutical company’s stock valued at $5,181,000 after buying an additional 993 shares during the last quarter. Wescott Financial Advisory Group LLC boosted its holdings in shares of Gilead Sciences by 5.4% in the fourth quarter. Wescott Financial Advisory Group LLC now owns 3,553 shares of the biopharmaceutical company’s stock valued at $328,000 after acquiring an additional 182 shares during the period. Annis Gardner Whiting Capital Advisors LLC grew its position in shares of Gilead Sciences by 158.8% during the fourth quarter. Annis Gardner Whiting Capital Advisors LLC now owns 352 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 216 shares during the last quarter. Finally, Pitcairn Co. increased its holdings in shares of Gilead Sciences by 4.0% in the 4th quarter. Pitcairn Co. now owns 6,845 shares of the biopharmaceutical company’s stock valued at $632,000 after acquiring an additional 265 shares during the period. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.